We provide the first evidence that ZOL can affect the activin signaling pathway specifically in ER-ve breast cancer cell lines by a dual mechanism; decreasing secretion of follistatin and preventing nuclear localization of linker phosphorylated Smad2. The gene discussed is SMAD2; the disease is breast cancer.